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Summary
Background: Long‐term prophylaxis with subcutaneous (SC) administration of a
highly concentrated plasma‐derived C1‐esterase inhibitor (C1‐INH) formulation was
recently approved by the Food and Drug Administration for hereditary angioedema
(HAE) attack prevention.
Objective: To characterize the population pharmacokinetics of C1‐INH (SC)
(HAEGARDA®; CSL Behring) in healthy volunteers and HAE patients, and assess the
variability and influence of covariates on pharmacokinetics.
Methods: C1‐INH functional activity data obtained after administration of various
C1‐INH (intravenous; IV) and C1‐INH (SC) doses from 1 study in healthy volunteers
(n = 16) and 2 studies in subjects with HAE (n = 108) were pooled to develop a
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population pharmacokinetic model (NONMEM v7.2). Pharmacokinetic parameters
derived from steady‐state simulations based on the final model were also evaluated.
Results: C1‐INH functional activity following C1‐INH (SC) administration was
described by a linear one‐compartment model with first‐order absorption and elimi-
nation, with inter‐individual variability in all parameters tested. The mean population
bioavailability of C1‐INH (SC), and pharmacokinetic parameters for clearance (CL),
volume of distribution, and absorption rate were estimated to be ~43%, 1.03 mL/
hour/kg, 0.05 L/kg and 0.0146 hour−1, respectively. The effect of bodyweight on CL
of C1‐INH functional activity was included in the final model, estimated to be 0.74.
Steady‐state simulations of C1‐INH functional activity vs time profiles in 1000 vir-
tual HAE patients revealed higher minimum functional activity (Ctrough) levels after
twice‐weekly dosing with 40 IU/kg (~40%) and 60 IU/kg (~48%) compared with
1000 IU IV (~30%). Based on the population pharmacokinetic model, the median
time to peak concentration was ~59 hours and the median apparent plasma half‐life
was ~69 hours.
Conclusions and Clinical Relevance: Twice‐weekly bodyweight‐adjusted dosing of
C1‐INH (SC) exhibits linear pharmacokinetics and dose‐dependent increases in
Ctrough levels at each dosing interval. In this analysis, SC dosing led to maintenance
of higher Ctrough levels than IV dosing.
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1 | INTRODUCTION
Hereditary angioedema (HAE) is a rare autosomal dominant disease
characterized by clinical symptoms including angioedema without
urticaria or pruritus, generally affecting the subcutaneous (SC) tissues
of the trunk, limbs or face, or the submucosal tissues of the respira-
tory, gastrointestinal or genitourinary tracts.1-4 Without treatment,
acute attacks can be life‐threatening and may require hospitalization;
moreover, many patients experience impaired quality of life.1,2,5-7
Management of HAE involves the treatment of acute attacks, as well
as short‐ and long‐term prophylaxis in many patients.
Mutations on the SERPING1 gene encoding the C1‐esterase
inhibitor (C1‐INH) are responsible for the 2 most common types
of HAE, type I (hereditary angioedema with deficient C1‐INH;
85% of patients) and type II (hereditary angioedema with dysfunc-
tional C1‐_INH; 15% of patients).1,5,8,9 In healthy individuals,
C1‐INH acts on the plasma kallikrein‐bradykinin system to prevent
excess generation of bradykinin and thus spontaneous activation
of inflammatory reactions.1,5,10 An absence in or dysfunction of
C1‐INH is the primary abnormality in patients with HAE, and a
plasma‐derived C1‐INH twice‐weekly intravenous (IV) injection pro-
vides a safe and generally effective treatment to reduce attacks
of angioedema.1,5,11,12 Consensus guidelines recommend C1‐INH
prophylaxis in patients who do not achieve sufficient benefit from
on‐demand treatment.9,13-16
Prior to the development of C1‐INH (SC), the pharmacokinetics
(PK) of C1‐INH IV (Berinert®, CSL Behring, Marburg, Germany; 50 IU
C1‐INH/mL) were compared to a highly concentrated IV formulation
(1500 IU C1‐INH) in a phase I study of 16 healthy volunteers
(NCT01760343). The bioavailability of the 2 formulations was found
to be comparable, and the highly concentrated formulation safe to
use in patients. The safety, efficacy and PK characteristics of C1‐
INH (SC) (HAEGARDA®; CSL Behring), were then subsequently
demonstrated in 2 randomized trials; in the COMPACT phase II
study, twice‐weekly SC administration of a highly concentrated for-
mulation of C1‐INH for 4 weeks in patients with HAE demonstrated
increased trough C1‐INH functional activity in a dose‐dependent
manner, and was generally well tolerated.17 The results of the COM-
PACT phase III study evaluating the efficacy and safety of C1‐INH
(SC) showed that twice‐weekly 40 and 60 IU/kg significantly reduced
the rate of HAE attacks compared with placebo (P < 0.0001 for
both).18 In 2017, the US Food and Drug Administration (FDA)
approved C1‐INH (SC) (HAEGARDA®) for the routine prophylaxis of
HAE attacks in adolescent and adult patients.
The aim of the present analysis was to characterize the popula-
tion PK of C1‐INH (SC) (HAEGARDA®) in healthy volunteers and
patients with HAE and to identify demographic and clinical factors
that are potential determinants of PK variability. Simulations based
on the final population PK model to support dosing of C1‐INH (SC)
were evaluated.
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2 | METHODS
2.1 | Study medication
C1‐INH (SC) (HAEGARDA®, CSL Behring; CSL830) is a highly con-
centrated formulation of a human, plasma‐derived C1‐INH.17 C1‐INH
is a soluble single‐chain glycoprotein with 478 amino acid residues
and an apparent molecular weight of approximately 105 kDa—
around 50% of the total molecular mass results from post‐transla-
tional glycosylation of the protein. C1‐INH is present in normal
human plasma at concentrations of approximately 0.2 mg/mL, which
is equivalent to 1 unit/mL plasma.19-21 After reconstitution, the final
concentration of C1‐INH (SC) is 500 IU/mL, whereas that of the IV
formulation (Berinert) is 50 IU/mL.
2.2 | Study populations, dose regimens and
pharmacokinetic sampling
Data were obtained and pooled from 3 clinical studies: 1 study in
healthy volunteers and 2 studies in patients with HAE following
either IV or SC administration of C1‐INH.
2.2.1 | Study 1 (Healthy volunteers; NCT01760343)
This was a randomized, double‐blind, single‐centre, cross‐over phase
I study to evaluate the safety, bioavailability and PK of 2 formula-
tions of C1‐INH. A cohort of 16 healthy volunteers aged 18‐
45 years with body mass index (BMI) 18‐29 kg/m2 received a single
dose of the concentrated 1500 IU C1‐INH formulation or the estab-
lished C1‐INH (IV) formulation (Berinert; 50 IU/mL). Blood samples
were collected for the determination of C1‐INH functional activity in
plasma up to 24 hours post‐dose and then intermittently until Day
11 after dosing.
2.2.2 | Study 2 (Patients with HAE; NCT01576523)
This was an open‐label, dose‐ranging, cross‐over phase II study to
characterize the PK, pharmacodynamics (PD) and safety of C1‐INH
(SC) in patients with HAE (COMPACT phase II study). The study
included 18 patients with HAE who were allocated sequentially to a
single dose of C1‐INH (IV) followed by a dose of either 1500, 3000,
or 6000 IU C1‐INH (SC) twice‐weekly for 4 weeks. After a washout
period of up to 4 weeks, patients were allocated to another 4‐week
dosing period, such that each patient received 2 of the 3 doses. Full
details of the study design have been reported previously.17 Blood
samples were collected for the determination of C1‐INH functional
activity in plasma up to 48 hours post‐dose and then every day in
Week 4 until the end of dosing.
2.2.3 | Study 3 (Patients with HAE; NCT01912456)
This was a double‐blind, randomized, placebo‐controlled, cross‐over
study to evaluate the clinical efficacy and safety of C1‐INH (SC)
(COMPACT phase III study). Ninety patients aged ≥ 12 years with a
clinical diagnosis of HAE type I or II were randomly assigned
(1:1:1:1) to one of the 40 IU/kg C1‐INH (SC) (sequences 1, 2) or
60 IU/kg C1‐INH (SC) (sequences 3, 4) treatment sequences. Each
sequence consisted of 2 consecutive periods (Treatment Period 1
and Treatment Period 2) of up to 16 weeks each. During the treat-
ment periods, subjects administered C1‐INH or placebo via SC injec-
tion twice a week in a double‐blind cross‐over manner. Blood
samples were collected in weeks 3, 5, 8, 11 and 14, and at the end
of each period of the study to determine C1‐INH functional activity
in plasma. Available dosing information for the administration of on‐
demand rescue medication in patients was accounted for in the
model.
2.3 | PK measurements
Plasma C1‐INH functional activity was assessed by a validated chro-
mogenic assay (Berichrom C1‐inhibitor, Siemens Eschborn, Germany;
reference range: 70%‐130% of norm). All measurements were per-
formed at a central laboratory (CSL Behring GmbH). Plasma C1‐INH
functional activity and C1‐INH antigen were assessed in all 3 clinical
studies.
2.4 | PK analysis
2.4.1 | Model development
The PK population included subjects who received C1‐INH either as
an IV or SC dose, and contributed at least 1 measurable PK concen-
tration. C1‐INH functional activity data following C1‐INH (SC)
administration in the 3 studies were analyzed by nonlinear mixed
effects modelling using the software package NONMEM version 7.2
(ICON Development Solutions, Ellicot City, MD, USA), with the pre-
diction of population pharmacokinetics (PREDPP) model library and
NM‐TRAN subroutines.
Various PK models, including 1‐ and 2‐compartment models
with first‐order elimination, were evaluated to arrive at the model
that best characterized the measured data. PK parameters such
as clearance (CL), volume of distribution (Vd), bioavailability (F),
absorption rate constant (Ka) and baseline C1‐INH functional
activity were assessed during model development. PK parameters
were estimated using the first‐order conditional estimation
method with interaction. The following covariates were consid-
ered before the start of the analysis: bodyweight, gender, age,
HAE type (I or II), subject population (healthy or HAE patient),
baseline C1‐INH functional activity and region where the study
was conducted. Each covariate was evaluated individually based
on the range of values in the dataset, scientific interest, mecha-
nistic plausibility, exploratory graphics and previous reporting in
other patient populations. After visual exploration, a backward
elimination approach was employed to test covariates of interest
(ie, that showed a trend in the visual exploration), including body-
weight and age on CL and Vd.
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2.4.2 | Model evaluation (visual predictive check)
Model evaluation was conducted using the final model to simulate
1000 datasets based on bodyweight (the only covariate found to
influence clearance), sampling times and the dosing histories con-
tained in the dataset. The model was subjected to a nonparametric
bootstrap analysis, generating 1000 datasets through random sam-
pling with replacement from the original data, using the individual as
the sampling unit.
2.4.3 | Simulations
Based on the distribution of individual weights in a HAE population,
the final model was used to simulate plasma profiles of C1‐INH
functional activity in 1000 patients with HAE from first dose up
to steady state, following twice‐weekly dosing of 40 IU/kg (SC),
60 IU/kg (SC), 1000 IU (IV) or 2500 IU (IV).
3 | RESULTS
3.1 | PK population
A total of 124 subjects (108 with HAE and 16 healthy volunteers)
were included in the PK analysis dataset, which comprised of a total
of 2103 C1‐INH functional activity observations. Population demo-
graphics are summarized in Table 1.
3.2 | Population PK model
3.2.1 | Base model
C1‐INH functional activity was best described by a linear
one‐compartment PK model with first‐order absorption, when
administered subcutaneously with structural parameters for CL and
Vd, first‐order Ka, and baseline C1‐INH functional activity (Table S1),
where the mean population F of C1‐INH (SC) was fixed to the value
previously described.17 The observed C1‐INH functional activity was
modelled as the sum of the patient's endogenous C1‐INH plus
administered (exogenous) C1‐INH.
As expected, the baseline C1‐INH functional activity was unam-
biguously different between healthy subjects and those with HAE,
therefore separate baseline parameters were estimated for each
population.
3.2.2 | Full model
The relationships between the model parameters, and covariates of
clinical interest (gender, age and bodyweight) were examined visually
then added simultaneously to form a full model. The small number
of non‐Caucasian subjects included (<10% of the population) meant
that race could not be included as a covariate for the analysis. A
summary of the final PK parameter estimates is provided in Table 2.
The only statistically significant covariate effect was that of body-
weight on CL, which was accounted for in the final model by includ-
ing bodyweight as a covariate on CL (Table 2).
The final model can be described by the following equation:
CL ¼ 0:830  WT
80:5
 0:738
In which CL is the individual value of clearance, and WT the
bodyweight of the subject (median 80.5 kg). Overall, age and gender
did not have an effect on the PK of C1‐INH functional activity. Addi-
tionally, a comparison of age as a binary effect (categorized as
>17 years [n = 117] vs ≤17 years [n = 7]) did not show a relevant
difference in the PK of C1‐INH functional activity in adults and ado-
lescents.
TABLE 1 Summary of population demographics by study
Covariate Statistic or category Study 1 Study 2 Study 3 Overall
Total number
Age (years) at baseline Median (Min‐Max) 35.0 (24‐45) 33.5 (18‐69) 40.0 (12‐72) 38.5 (12‐72)
Weight (kg) at baseline Median (Min‐Max) 73.7 (54‐108) 78.9 (51‐110) 78.1 (43‐157) 77.6 (43‐157)
Observed baseline C1‐INH
functional activity (%)
Mean (Min‐Max) 99.8 (79‐149) 17.9 (0‐43) 28.6 (4.5‐77) 36.5 (0‐149)
Gender (N) Male 11 7 30 48
Female 5 11 60 76
Race (N) Caucasian 16 14 84 114
Asian – 4 4 8
Black – – 1 1
Other – – 1 1
HAE type (N) Type I
NA
16 78 94
Type II 2 12 14
Total number of samples 496 545 1062 2103
C1‐INH, C1‐esterase inhibitor; HAE, hereditary angioedema; Max, maximum; Min, minimum; N, total number of subjects; NA, not assessed.
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3.2.3 | Final model evaluation
The observed concentrations for healthy subjects and patients at the
10th and 90th percentiles and median were inspected for agreement
with simulated concentrations at the 10th, 50th and 90th per-
centiles. This assessment did not indicate any substantive deficiency
in the ability of the final reference model to characterize trends and
variability in the observed PK data (Figure S1).
Visual evaluation of the individual post‐hoc estimates revealed
that CL was lower in patients enrolled in Study 2 (COMPACT II)
compared to Study 3 (COMPACT III). This was quantified in the
final model as a categorical covariate and the CL was estimated
to be 40% lower in Study 2. The individual post-hoc CL and Vd
estimates from the 2 models showed no difference. On further
evaluation of the distribution of the individual estimates in each
study, it became apparent that in order to gain an assessment of
population PK parameters in subjects with HAE, the population
CL estimate from the pooled model best reflected the overall
HAE population, as Study 2 appears to be a small subset of the
overall population in the analysis. A test of the effects of baseline
C1‐INH values, starting bodyweight and Vd failed to explain these
differences.
3.2.4 | Simulations of C1‐INH (SC) vs C1‐INH (IV)
A summary of the model‐predicted geometric mean maximum plasma
C1‐INH functional activity levels (Cmax), minimum functional activity
levels (Ctrough), median time to peak concentration (Tmax), half‐life and
area under the activity‐time curve from pre‐dose to the end of the
dosing interval at steady state (AUC0-τ) are presented in Table 3.
Based on the final model, mean Cmax was 48.7% for 40 IU/kg and
60.7% for 60 IU/kg, and 56.3% and 104% for 1000 IU and 2500 IU
C1‐INH (IV). Mean Ctrough was 40.2% for 40 IU/kg and 48.0% for
60 IU/kg; these values were higher than the 29.5% and 37.8% calcu-
lated with 1000 IU and 2500 IU C1‐INH (IV) (Figure 1). The median
Tmax of ~59 hours is characteristic of SC administration of proteins.
The simulated C1‐INH functional activity curves showed a lower
peak‐to‐trough ratio with a more consistent elevation of the C1‐INH
functional activities for the 40 and 60 IU/kg SC doses (1.2 and 1.3,
respectively) compared to those after 1000 and 2500 IU IV doses
(1.9 and 2.8, respectively) (Figure 1).
4 | DISCUSSION
This analysis demonstrated that the PK of C1‐INH (SC) was best
described by a one‐compartment model with first‐order absorption
and first‐order elimination. Bodyweight was found as the only signifi-
cant covariate describing CL (with the weight exponents on CL esti-
mated to be 0.74 in the final model). To illustrate the magnitude of
this effect, a subject with a baseline weight of 60 kg would have a CL
of 0.67 IU/hour· %, whereas a subject with a baseline weight of 90 kg
would have a CL of 0.90 IU/hour· %. The absorption rate was
0.0146 hour−1. The Ctrough of 60 IU/kg C1‐INH (SC), twice‐weekly was
simulated to be 48.0%, compared to 30% of 1000 IU C1‐INH (IV)
twice‐weekly. For C1‐INH (SC), the population mean bioavailability
(~43%), CL (1.03 mL/hour/kg) and Vd (0.05 L/kg) are consistent with
previous estimates reported in the literature.22-25 The model absorp-
tion rate of 0.0146 hour−1 for SC dosing is reflective of the slow
transport through the lymphatic system, which is thought to play a
major role in the SC absorption of large molecules—such as C1‐INH
which has a molecular weight of approximately 105 kDa.25,26
The current analysis is a comprehensive pooled population PK
analysis conducted using data from 3 clinical studies, and is thus a
more comprehensive characterization of C1‐INH population PK in the
entire HAE population. The lower CL estimates in Study 2 compared
to Study 3 are most likely due to the smaller sample size in Study 2, or
due to the higher rate of HAE attacks prior to screening in Study 3,
which may have an impact on the CL of C1‐INH (SC). The consump-
tion of C1‐INH during a HAE attack has not previously been charac-
terized and therefore the C1‐INH kinetics cannot be quantified.
Until recently, C1‐INH was only used as an IV formulation. The
PK of C1‐INH (IV) has been described by Martinez‐Saguer et al27
who demonstrated the median half‐lives of functional C1‐INH plasma
levels to be 39.1 hours after on‐demand therapy and 30.9 hours for
patients on individual replacement therapy. The PK profile of C1‐INH
TABLE 2 Final population pharmacokinetic parameter estimates
Parameter (units)
NONMEM estimates
Point estimate %RSE %IIV %RSE
CL (IU/h∙%) 0.830* 6.40 24.2 22.9
Vd (IU/%) 43.3
† 9.60 39.2 32.2
Ka (h
−1) 0.0146 16.1 82.2 14.5
BASE (%)
(Healthy volunteers; h)
105 3.20 11.03 17.8
BASE (%) (HAE subjects; h) 23.2 3.68 29.5 9.76
F 0.427 FIX 49.1 12.6
Effect of bodyweight on CL 0.738 23.8
Inter‐individual or inter‐occasion variability
ω2CL 0.0587
ω2V 0.153
ω2BASEHV 0.0122
ω2BASEHAE 0.0868
ω2Ka 0.675
ω2F 0.241
Residual variability CV% %RSE
σ2prop 23.4 5.10
%RSE, percent relative standard error of the estimate = SE/parameter
estimate * 100; σ2prop, proportional component of the residual error
model; 95% CI, 95% confidence interval on the parameter; CL, clearance;
CV, coefficient of variation of proportional error (=[σ2prop]
0.5 * 100);
F, bioavailability; h, hours; HAE, hereditary angioedema; HV, healthy vol-
unteer; IIV, inter‐individual variability; Ka, absorption rate constant; NA,
not applicable; ω2, variance of inter‐individual variability parameter; Vd,
volume of distribution.
*CL = 1.03 mL/h/kg
†Vd = 0.05 L/kg.
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(SC) is different from that of C1‐INH (IV). Due to the longer absorp-
tion phase after SC administration and the proposed lymphatic trans-
port of C1‐INH (SC), the Tmax is estimated to be ~59 hours and the
apparent half‐life ~69 hours, resulting in higher trough levels at the
next dosing interval with twice‐weekly dosing. Simulations of 40 and
60 IU/kg twice‐weekly dosing of C1‐INH (SC) have calculated a mean
Ctrough of 40.2% and 48.0% C1‐INH functional activity, respectively,
which were higher than the 29.5% Ctrough values estimated after
1000 IU C1‐INH (IV). Even with the highest dose of 2500 IU C1‐INH
(IV) twice‐weekly, the Ctrough values were estimated to be 39%, which
is lower than that found for C1‐INH (SC) at the 60 IU/kg dose. With
the FDA‐approved bodyweight dosing of 60 IU/kg, simulations sug-
gest that the majority of patients will have Ctrough values above the
clinically meaningful 40% threshold, below which patients are more
likely to experience attacks.24
The differences in calculated Ctrough values suggest that
patients with HAE who administer C1‐INH (SC) prophylaxis may
experience less time having lower C1‐INH functional activity com-
pared to those who administer IV prophylaxis. Results from an
exposure‐response analysis of the relationship between C1‐INH
functional activity and risk of HAE attacks confirmed that a
greater reduction in the relative risk of a HAE attack correlates
with increasing C1‐INH functional activities.28 Thus, maintenance
of higher Ctrough values after SC prophylaxis compared to IV pro-
phylaxis offers greater protection to HAE patients from experienc-
ing a HAE attack.
TABLE 3 Summary of pharmacokinetic parameters of steady‐state C1‐INH (SC) from the simulation population stratified by dose
Dose Cmax (%) Tmax
a (h) Ctrough (%) AUC0-τ (%·h) Apparent half‐lifea,b (h)
40 IU/kg SC 48.7 (26.9‐96.2) 58.7 (23‐134) 40.2 (22.2‐77.9) 1700 (558‐5110) 68.7 (24.0‐250)
60 IU/kg SC 60.7 (31.8‐128) 58.7 (23‐134) 48.0 (25.1‐102) 2540 (837‐7670) 68.7 (24.0‐251)
1000 IU IV 56.3 (38.9‐81.7) ‐ 29.5 (16.9‐49.7) 98,400 (61,200‐162,000) ‐
2500 IU IV 104 (69.7‐160) ‐ 37.8 (19.6‐70.2) 246,000 (153,000‐404,000) ‐
AUC0-τ, area under the activity‐time curve from predose to the end of the dosing interval at steady state; Cavg, average plasma C1‐INH functional activ-
ity at steady state; Cmax, maximum plasma C1‐INH functional activity levels; Cmin, minimum plasma C1‐INH functional activity levels; Ctrough, minimum
plasma C1‐INH functional activity levels; h, hours; IU, international unit; SC, subcutaneous; Tmax, time to maximum activity.
Data presented as geometric mean (95% CI).
aData presented as median (95% CI).
bCalculated using a non‐compartmental analysis module in Phoenix©.
(A)
(B)
F IGURE 1 Simulated median steady‐
state C1‐INH functional activity vs time
after twice‐weekly C1‐INH (SC) 40 IU/kg,
C1‐INH (SC) 60 IU/kg, C1‐INH (IV)
1000 IU, and C1‐INH (IV) 2500 IU (A).
Simulated median (90% CI) simulated
C1‐INH functional activity time profiles for
twice‐weekly 60 IU/kg C1‐INH (SC) and
1000 IU (C1‐INH (IV) (B)
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Performing a pooled population PK analysis enabled the inclusion
of data from all studies, including sparse data, from the phase III
study to characterize the PK of C1‐INH (SC). A population PK analy-
sis of the phase II study provided a good description of C1‐INH
functional activity and revealed a significant effect of bodyweight on
CL.17 The use of population modelling throughout the process
assisted in designing studies with optimal samples for PK and to
make comparisons of various dosing scenarios without conducting
the clinical trials.
In conclusion, our analysis demonstrates that in patients with
HAE, long‐term prophylaxis with bodyweight‐based SC dosing of C1‐
INH provides consistent and higher trough levels of C1‐INH func-
tional activity at the next dosing interval compared with IV route of
administration at the currently recommended dosing (1000 IU and
2500 IU twice‐weekly).
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